Navigation Links
Children's National researcher receives ACCP Distinguished Investigator Award
Date:9/8/2008

The American College of Clinical Pharmacology (ACCP) has awarded John van den Anker, MD, PhD, director of Pediatric Clinical Pharmacology at Children's National Medical Center, its annual Distinguished Investigator Award.

Dr. van den Anker, a neonatologist by training, receives this award for "his sustained and prolific contributions to pediatric clinical pharmacology," according to the ACCP.

The Distinguished Investigator Award is given yearly and recognizes superior scientific expertise and accomplishments by a senior investigator, usually involving a distinct area of research in basic or clinical pharmacology for which the individual is internationally known.

Dr. van den Anker is the director of Pediatric Clinical Pharmacology at Children's National Medical Center, and also serves as associate director of Children's Research Institute's Center for Clinical and Community Research. He is professor of Pediatrics, Pharmacology, and Physiology at the George Washington University School of Medicine and Health Sciences, and holds the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology at Children's National. He has received several major awards from the National Institutes of Health and has published more than 150 peer reviewed papers in the field of neonatal and pediatric clinical pharmacology. He also served as the president of the European Society of Developmental, Perinatal, and Pediatric Pharmacology from 2006-2008.


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. Corporate Safe Specialists Launches International Sales Efforts
2. New chemical radar among national security innovations in ACS podcast
3. International team reveals first prognosticator of survival in aggressive cancer
4. White House announces 2007 National Medal of Science laureates
5. National security remedies among topics at surveillance confab
6. Duke Medicine physician-scientist receives National Medal of Science
7. National Research Council report on security at federally managed dams
8. Food, health get top billing at national chemistry meeting
9. Childrens national co-leads nationwide study of landmark sickle cell treatment
10. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2008
11. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: